Project Grant K08AI202748
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $264,750 to the University of Washington on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of three transcriptional regulators—DR1, DRAP1, and BTAF1—in suppressing interferon responses triggered by self-RNA ligands. The research characterizes how loss of these proteins induces robust interferon responses and explores the immunostimulatory double-stranded RNA...
- The National Institute of Allergy and Infectious Diseases awarded $489,500 to Benaroya Research Institute at Virginia Mason on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify molecular mechanisms that inhibit CNS resident memory T cells driving neuroinflammation in multiple sclerosis. The project investigates CNS CD4+ tissue resident memory T cells (TRM) as a reservoir of autoreactive cells that sustains MS disease activity and resists...
- The National Institute of Allergy and Infectious Diseases awarded $267,000 to the Benaroya Research Institute at Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into circulating and mucosal immune cell populations affected by therapeutic interleukin-23 blockade in Crohn's disease patients treated with risankizumab. The project will quantify and characterize TH17 cells, mucosa-associated invariant T cells,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded Benaroya Research Institute At Virginia Mason $267,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of shared T cell receptor alpha-chain junctions in Type 1 Diabetes autoimmunity. The project examines human islet antigen-reactive CD4+ memory T cells from peripheral blood and their relationship to pancreatic-infiltrating T cells. Prior cross-sectional analysis...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $136,563 on November 28, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a nanoparticle formulation for selective delivery of short-chain fatty acids to the distal gut as a treatment for multiple sclerosis-related central nervous system autoimmunity. The project targets the gut-central nervous system axis by addressing translational barriers to oral...
- The National Institute of Allergy and Infectious Diseases awarded Cornell University $2.8 million on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate post-transcriptional regulation of pathogenic T helper 17 (TH17) cell function. The project focuses on how CD28 signaling modulates TH17 differentiation and function through the PIP5K1A-ARS2 axis, with application to multiple sclerosis and other autoimmune diseases. The research builds on...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $2.719 million on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define a unifying framework for how type 2 immune responses are initiated, maintained, and recalled across barrier tissues. The award funds four interdependent research projects addressing distinct tissue contexts. Project 1 defines a neuro-epithelial-immune circuit in the small intestine...
- The National Institute of Allergy and Infectious Diseases awarded $2.684 million to Benaroya Research Institute at Virginia Mason on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct deep analysis of epitope-specific CD4+ T cells before the onset of Type 1 Diabetes. The research investigates how self-reactive CD4+ T cell responses evolve in at-risk individuals prior to T1D disease onset. The project will characterize longitudinal changes in...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...